Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 12/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.38 |
| ▸ | CDK2 | P24941 | 12/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190557 | 1.00 | ERN1 (0.53) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22190558 | 1.00 | ERN1 (0.53) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22200691 | 1.00 | ERN1 (0.53) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22190888 | 0.90 | ERN1 (0.59) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL29353001 | 0.90 | ERN1 (0.59) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22190890 | 0.90 | ERN1 (0.59) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL25035591 | 0.90 | ERN1 (0.56) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22200443 | 0.87 | ERN1 (0.45) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22190707 | 0.86 | ERN1 (0.54) | ERN1BRAFCCND1CCNE1CDK2 | |
| SCHEMBL22191839 | 0.86 | ERN1 (0.54) | ERN1BRAFCCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885CCND1 1637/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885CCND1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.